临床试验/NCT07761598

NCT07761598尚未招募不适用

The TERUMO FRED X EARLY FEASIBILITY STUDY (FAST) STUDY.

Jacobs institute1 个研究点分布在 1 个国家目标入组 15 人开始时间: 2026年8月1日最近更新: 2026年8月12日

适应症

干预措施

试验速览

阶段: 不适用
状态: 尚未招募
发起方
入组人数: 15
试验地点: 1
主要终点: A thromboembolic event in the territory supplied by the treated artery.

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The TERUMO FRED X EARLY FEASIBILITY STUDY (FAST) is a prospective, single-arm investigation.

详细描述

The FAST study is an Early Feasibility Study (EFS), prospective, open-label, single-arm, unblinded, fifteen (n=15) patient investigation

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 22 Years 至 85 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Subject has a single untreated target IA.

排除标准

•Subject with anatomy not appropriate for endovascular treatment.

研究组 & 干预措施

Single arm study for a medical device for the FREDX device for aneurysm cerebral treatment with DAPT

Experimental

干预措施: Fred X Medical Device Intervention for Aneurysm Treatment with DAPT Therapy. (Device)

结局指标

主要结局

A thromboembolic event in the territory supplied by the treated artery.

时间窗: 12 months

A thromboembolic event in the territory supplied by the treated artery.

次要结局

未报告次要终点

研究者

发起方

Jacobs institute

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

LUMENS-1 Canada Early Feasibility Study Clinical Investigation PlanBrain Aneurysm

NCT07259018LuSeed Vascular LTD.10

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's DiseaseCrohn Disease

NCT07483099Eli Lilly and Company60

Early Feasibility Study to Assess the Safety and Effectiveness of the OnePoint Dialysis CannulaTM as a Single-Site Vascular Access Device for Hemodialysis ProceduresVascular Access

NCT07599085Evolve Medicus, Inc.20

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917Aminex Therapeutics, Inc.92

进行中（未招募）

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)

NCT07300085Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)710